{"hands_on_practices": [{"introduction": "Precision in surgical oncology begins with the fundamentals of pharmacology and accurate dose administration. This first exercise grounds the advanced technique of sentinel lymph node (SLN) mapping in a core, practical skill: calculating the precise dose of the fluorescent tracer, Indocyanine Green (ICG). By applying basic principles of concentration, volume, and mass, you will ensure a standardized and effective start to the mapping procedure, which is the cornerstone of its success.", "problem": "In fluorescence-guided sentinel lymph node mapping for endometrial or vulvar cancer, Indocyanine Green (ICG) is injected into the cervix at multiple sites to facilitate lymphatic visualization. Assume the following scientifically standard and widely used preparation and administration approach: a solution of ICG has a concentration of $1.25$ milligrams per milliliter, and the cervix is injected at $4$ quadrants with equal volume at each site. The injection volume per site is $0.5$ milliliters. Assume no loss of injectate to leakage or degradation at the moment of administration, and that the injected solution is homogeneous.\n\nUsing only fundamental definitions relating concentration, mass, and volume, determine the total ICG dose administered across all injection sites. Round your answer to two significant figures. Express the final dose in milligrams.", "solution": "The problem requires the calculation of the total mass of Indocyanine Green (ICG) administered based on given concentration and injection volumes.\n\n### Step 1: Extract Givens\nThe explicit data and conditions provided in the problem statement are:\n-   Concentration of ICG solution, $C$: $1.25$ milligrams per milliliter.\n-   Number of injection sites, $N_{sites}$: $4$ quadrants.\n-   Injection volume per site, $V_{site}$: $0.5$ milliliters.\n-   Condition 1: The volume injected at each site is equal.\n-   Condition 2: There is no loss of injectate to leakage or degradation at the moment of administration.\n-   Condition 3: The injected solution is homogeneous.\n-   Requirement: The final answer must be rounded to two significant figures and expressed in milligrams.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is subjected to validation against the specified criteria.\n\n-   **Scientifically Grounded**: The problem describes a standard clinical procedure for sentinel lymph node mapping. The use of ICG, its concentration ($1.25 \\, \\text{mg/mL}$), the number of injection sites ($4$), and the volume per site ($0.5 \\, \\text{mL}$) are all consistent with established medical practice. The calculation is based on the fundamental definition of concentration ($C = \\frac{m}{V}$), a core principle in chemistry and pharmacology. The problem is scientifically sound.\n-   **Well-Posed**: All necessary information to determine the total mass is provided. The givens are sufficient and lead to a unique solution.\n-   **Objective**: The problem is stated using precise, quantitative language. It is free from subjective claims or ambiguity.\n\nThe problem does not exhibit any of the listed invalidating flaws. It is self-contained, consistent, realistic, and solvable through formal reasoning.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A solution will be derived.\n\n### Solution Derivation\nThe fundamental relationship between mass ($m$), concentration ($C$), and volume ($V$) is given by the definition of concentration:\n$$C = \\frac{m}{V}$$\nTo find the mass of a substance in a solution of known concentration and volume, this equation is rearranged to:\n$$m = C \\times V$$\n\nFirst, we must determine the total volume of the ICG solution administered. The problem states there are $N_{sites} = 4$ injection sites, and the volume injected at each site is $V_{site} = 0.5 \\, \\text{mL}$. The total volume, $V_{total}$, is the sum of the volumes at each site. Since the volume is equal at all sites, we can calculate the total volume as:\n$$V_{total} = N_{sites} \\times V_{site}$$\nSubstituting the given values:\n$$V_{total} = 4 \\times 0.5 \\, \\text{mL} = 2.0 \\, \\text{mL}$$\n\nNext, we calculate the total mass of ICG, $m_{total}$, using the total volume $V_{total}$ and the given concentration $C = 1.25 \\, \\frac{\\text{mg}}{\\text{mL}}$.\n$$m_{total} = C \\times V_{total}$$\nSubstituting the values for concentration and total volume:\n$$m_{total} = 1.25 \\, \\frac{\\text{mg}}{\\text{mL}} \\times 2.0 \\, \\text{mL}$$\nPerforming the multiplication:\n$$m_{total} = 2.5 \\, \\text{mg}$$\n\nThe problem requires the final answer to be rounded to two significant figures. The calculated value is $2.5$. The digit '$2$' is significant, and the digit '$5$' is significant. Therefore, the number $2.5$ already has exactly two significant figures. No further rounding is necessary.\n\nThe total dose of ICG administered is $2.5$ milligrams.", "answer": "$$\\boxed{2.5}$$", "id": "4508970"}, {"introduction": "Moving from procedural execution to critical appraisal, we must evaluate how well a diagnostic test performs. Understanding the statistical power of SLN mapping is essential for evidence-based decision-making and for counseling patients on its reliability. This practice will guide you through calculating the fundamental performance metrics—such as sensitivity, specificity, and predictive values—from clinical trial data, transforming raw numbers into a meaningful assessment of the technique's accuracy [@problem_id:4509009].", "problem": "A prospective cohort of patients with apparently early-stage endometrial cancer undergoes sentinel lymph node (SLN) mapping using indocyanine green fluorescence. Final comprehensive histopathology with ultrastaging is used as the reference standard for nodal metastasis. The SLN mapping test results, when cross-tabulated against the reference standard, yield the following counts: true positives $TP=70$, false negatives $FN=2$, false positives $FP=5$, and true negatives $TN=123$. Using the standard definitions of diagnostic test performance metrics grounded in conditional probability (that is, the probability of a test result conditional on true disease status), compute the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and false negative rate (FNR) of SLN mapping in this cohort. Express each metric as a decimal and round your answers to four significant figures. Provide your final five values in a single row matrix in the order: sensitivity, specificity, PPV, NPV, FNR.", "solution": "The problem is subjected to validation and is deemed valid. It is scientifically grounded, well-posed, objective, and contains all necessary information for a unique solution. The data provided are consistent and plausible within the context of clinical diagnostics for sentinel lymph node (SLN) mapping in oncology.\n\nThe problem requires the calculation of five standard performance metrics for a diagnostic test: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and false negative rate (FNR). These metrics are defined based on conditional probabilities derived from a $2 \\times 2$ contingency table, which cross-tabulates the test results against the true disease status (the reference standard).\n\nLet $D^+$ denote the event that a patient has nodal metastasis (disease is present), and $D^-$ denote the event that a patient does not have nodal metastasis (disease is absent). Let $T^+$ denote a positive test result (SLN mapping indicates metastasis), and $T^-$ denote a negative test result.\n\nThe provided data are the counts for the four possible outcomes:\n- True Positives ($TP$): The number of patients with the disease who test positive. Given as $TP = 70$.\n- False Negatives ($FN$): The number of patients with the disease who test negative. Given as $FN = 2$.\n- False Positives ($FP$): The number of patients without the disease who test positive. Given as $FP = 5$.\n- True Negatives ($TN$): The number of patients without the disease who test negative. Given as $TN = 123$.\n\nFrom these fundamental counts, we can calculate the marginal totals:\n- Total number of patients with the disease: $P = TP + FN = 70 + 2 = 72$.\n- Total number of patients without the disease: $N = FP + TN = 5 + 123 = 128$.\n- Total number of patients with a positive test: $TP + FP = 70 + 5 = 75$.\n- Total number of patients with a negative test: $FN + TN = 2 + 123 = 125$.\n- Total number of patients in the cohort: $TP + FN + FP + TN = 70 + 2 + 5 + 123 = 200$.\n\nNow, we define and compute each requested metric.\n\n1.  **Sensitivity** (also known as the True Positive Rate, TPR) is the probability of a positive test result, conditional on the patient having the disease.\n    $$\n    \\text{Sensitivity} = P(T^+ | D^+) = \\frac{TP}{TP + FN}\n    $$\n    Substituting the given values:\n    $$\n    \\text{Sensitivity} = \\frac{70}{70 + 2} = \\frac{70}{72} \\approx 0.972222...\n    $$\n    Rounding to four significant figures, we get $0.9722$.\n\n2.  **Specificity** (also known as the True Negative Rate, TNR) is the probability of a negative test result, conditional on the patient not having the disease.\n    $$\n    \\text{Specificity} = P(T^- | D^-) = \\frac{TN}{TN + FP}\n    $$\n    Substituting the given values:\n    $$\n    \\text{Specificity} = \\frac{123}{123 + 5} = \\frac{123}{128} \\approx 0.9609375\n    $$\n    Rounding to four significant figures, we get $0.9609$.\n\n3.  **Positive Predictive Value (PPV)** is the probability of a patient having the disease, conditional on receiving a positive test result. This is an application of Bayes' theorem.\n    $$\n    \\text{PPV} = P(D^+ | T^+) = \\frac{TP}{TP + FP}\n    $$\n    Substituting the given values:\n    $$\n    \\text{PPV} = \\frac{70}{70 + 5} = \\frac{70}{75} = \\frac{14}{15} \\approx 0.933333...\n    $$\n    Rounding to four significant figures, we get $0.9333$.\n\n4.  **Negative Predictive Value (NPV)** is the probability of a patient not having the disease, conditional on receiving a negative test result.\n    $$\n    \\text{NPV} = P(D^- | T^-) = \\frac{TN}{TN + FN}\n    $$\n    Substituting the given values:\n    $$\n    \\text{NPV} = \\frac{123}{123 + 2} = \\frac{123}{125} = 0.984\n    $$\n    To express this with four significant figures, we write $0.9840$.\n\n5.  **False Negative Rate (FNR)** is the probability of a negative test result, conditional on the patient having the disease. It is the complement of sensitivity.\n    $$\n    \\text{FNR} = P(T^- | D^+) = \\frac{FN}{TP + FN} = 1 - \\text{Sensitivity}\n    $$\n    Substituting the given values:\n    $$\n    \\text{FNR} = \\frac{2}{70 + 2} = \\frac{2}{72} = \\frac{1}{36} \\approx 0.027777...\n    $$\n    Rounding to four significant figures, we get $0.02778$.\n\nThe five computed metrics, rounded to four significant figures, are:\n- Sensitivity: $0.9722$\n- Specificity: $0.9609$\n- PPV: $0.9333$\n- NPV: $0.9840$\n- FNR: $0.02778$\n\nThese values are to be presented in a single row matrix in the specified order.", "answer": "$$\n\\boxed{\\begin{pmatrix} 0.9722 & 0.9609 & 0.9333 & 0.9840 & 0.02778 \\end{pmatrix}}\n$$", "id": "4509009"}, {"introduction": "The operating room often presents challenges that require integrating theoretical knowledge with real-time problem-solving. This final practice simulates a complex intraoperative scenario where dual-tracer signals are discordant, a common dilemma in SLN mapping. To resolve this, you must apply your understanding of tracer physics, lymphatic anatomy, and established clinical algorithms, demonstrating the synthesis of skills required to ensure accurate nodal staging even when faced with unexpected findings [@problem_id:4508888].", "problem": "A patient with apparent stage $\\text{I}$ endometrial adenocarcinoma undergoes minimally invasive sentinel lymph node (SLN) mapping using dual tracers: technetium-99m radiocolloid injected cervically at $3$ and $9$ o’clock and Indocyanine Green (ICG) for Near-Infrared (NIR) fluorescence. Approximately 2 hours after injection and at the start of pelvic lymphatic exploration, the left pelvis shows the following discordant signals: an ICG-fluorescent node in the obturator fossa with low gamma counts ($\\approx 200$ counts per second), and a nearby external iliac region hot focus with high gamma counts ($\\approx 1500$ counts per second) but no apparent fluorescence. Ambient lights are partially dimmed, and the gamma probe is collimated in standard fashion. There is a cervical injection depot visible on the left. The right pelvis maps normally with a single ICG-positive, gamma-avid node.\n\nStarting from the core definitions of a sentinel node as the first nodal basin receiving lymphatic flow from the primary, the physical basis of detection by gamma scintillation (penetrating photons obeying an inverse-square relationship of detected intensity with source distance) and by NIR fluorescence (excitation-emission limited by tissue absorption following Beer–Lambert behavior), and the widely accepted algorithmic principle that dual-tracer discordance warrants evaluation of both signals before deciding on node harvest, which of the following is the most appropriate immediate troubleshooting sequence and operative decision on the left side to maximize true SLN identification while minimizing false positives?\n\nA. First shield the cervical injection site to reduce gamma shine-through and re-orient the gamma probe to interrogate the hot focus from multiple angles; concurrently optimize NIR imaging by further reducing ambient light, adjusting camera gain and focus, and gently mobilizing overlying fat to decrease path length; confirm that the hot focus corresponds to a discrete nodal structure with a lymphatic pedicle rather than contamination; then harvest both the ICG-positive low-count node and the gamma-avid non-fluorescent node with ex vivo confirmation of gamma counts and NIR signal; if mapping remains discordant or fails unilaterally after optimization, proceed with side-specific lymphadenectomy per guideline.\n\nB. Ignore the ICG-positive node due to its low gamma counts and remove only the hottest gamma focus, attributing the lack of fluorescence to deep location, without further optimization or verification steps.\n\nC. Abandon the current mapping by immediately re-injecting both technetium-99m and ICG and restarting the procedure, discarding any nodes currently identified to avoid discordance.\n\nD. Attribute the hot, non-fluorescent focus to cervical injection-site shine-through and avoid removing any node on the left side; proceed only with contralateral mapping, since bilateral mapping is not required when one side is adequate.\n\nE. Clip the lymphatic channel proximal to the fluorescent node to prevent further tracer spread, then increase NIR excitation power and rely exclusively on fluorescence to select the node, setting the gamma probe aside on the left.", "solution": "The user requires a critical validation of the provided problem statement, followed by a detailed solution and evaluation of all options.\n\n### Step 1: Extract Givens\n\n-   **Patient Condition**: Apparent stage $\\text{I}$ endometrial adenocarcinoma.\n-   **Procedure**: Minimally invasive sentinel lymph node (SLN) mapping.\n-   **Tracers**:\n    1.  Technetium-99m ($^{\\text{99m}}\\text{Tc}$) radiocolloid, injected cervically at $3$ and $9$ o’clock.\n    2.  Indocyanine Green (ICG), injected cervically for Near-Infrared (NIR) fluorescence.\n-   **Timing**: Pelvic exploration starts approximately 2 hours after injection.\n-   **Findings (Left Pelvis)**:\n    1.  An ICG-fluorescent node in the obturator fossa with low gamma counts ($\\approx 200$ counts per second).\n    2.  A nearby external iliac region hot focus with high gamma counts ($\\approx 1500$ counts per second) but no apparent fluorescence.\n-   **Intraoperative Conditions**:\n    -   Ambient lights are partially dimmed.\n    -   Gamma probe is collimated in standard fashion.\n    -   A cervical injection depot is visible on the left.\n-   **Findings (Right Pelvis)**: Normal mapping with a single ICG-positive, gamma-avid node.\n-   **Stated Principles for Evaluation**:\n    1.  Definition of SLN: The first nodal basin receiving lymphatic flow.\n    2.  Physical Basis of Detection:\n        -   Gamma scintillation (Tc-99m): Penetrating photons, inverse-square law ($I \\propto 1/r^2$).\n        -   NIR fluorescence (ICG): Excitation-emission limited by tissue absorption (Beer–Lambert behavior).\n    3.  Algorithmic Principle: Dual-tracer discordance warrants evaluation of both signals before deciding on node harvest.\n-   **Question**: Identify the most appropriate immediate troubleshooting sequence and operative decision on the left side to maximize true SLN identification while minimizing false positives.\n\n### Step 2: Validate Using Extracted Givens\n\n1.  **Scientifically Grounded**: The problem is firmly grounded in the established medical and physics principles of sentinel lymph node mapping in gynecologic oncology. The tracers (Tc-99m, ICG), detection modalities (gamma probe, NIR camera), anatomical locations, and the phenomenon of discordant mapping are all standard and accurately described. The underlying physics principles cited—the inverse-square law for gamma photon detection and the Beer–Lambert law for optical attenuation—are correct and relevant to the detection technologies. The clinical dilemma is realistic and a frequent point of discussion and research in the field.\n\n2.  **Well-Posed**: The problem is well-posed. It presents a specific clinical scenario with quantitative and qualitative data and asks for the \"most appropriate\" course of action from a list of choices, based on a clear objective (\"maximize true SLN identification while minimizing false positives\"). A single best answer can be determined through logical application of the stated principles and established clinical guidelines.\n\n3.  **Objective**: The language is technical, precise, and free of subjective bias. It describes a set of observations and asks for a decision based on scientific and procedural logic.\n\n4.  **Flaw Checklist**:\n    -   **Scientific/Factual Unsoundness**: None. The scenario is entirely sound.\n    -   **Non-Formalizable/Irrelevant**: None. The problem is a direct and formalizable application of clinical decision-making.\n    -   **Incomplete/Contradictory Setup**: None. The information provided is sufficient. The discordance between the two signals is the core of the problem to be solved, not a contradiction in the problem's setup. The mention of the \"cervical injection depot\" is a critical piece of data that points toward a known potential artifact (shine-through).\n    -   **Unrealistic/Infeasible**: None. This is a realistic and common intraoperative scenario.\n    -   **Ill-Posed/Poorly Structured**: None. A unique best course of action among the options can be identified.\n    -   **Pseudo-Profound/Trivial/Tautological**: None. The problem requires a nuanced understanding of two different technologies, their potential failure modes, and the clinical algorithm designed to reconcile them.\n    -   **Outside Scientific Verifiability**: None. The recommended procedures are based on evidence-based medicine and verifiable physical principles.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **VALID**. It is scientifically sound, well-posed, objective, and presents a realistic and non-trivial clinical challenge. I will proceed with the solution.\n\n### Solution Derivation\n\nThe problem requires determining the optimal sequence of actions to resolve a discordant sentinel lymph node mapping on the left side. The goal is to correctly identify the true sentinel node(s) according to established algorithms, which are designed to maximize sensitivity (minimize false negatives) while applying logical troubleshooting to minimize the removal of non-sentinel tissue (minimize false positives).\n\nThe situation is:\n1.  **ICG-positive node**: A node in the obturator fossa is fluorescent but has low gamma counts ($200$ cps). According to standard dual-tracer algorithms (e.g., the FILM or FIRES trial methodology), any node identified by either tracer is considered a potential SLN. Therefore, this node is a candidate SLN and cannot be ignored. The low counts do not disqualify it.\n2.  **Gamma-avid focus**: A location in the external iliac region is \"hot\" ($1500$ cps) but not fluorescent. There are two primary explanations for this:\n    a.  **True SLN**: It could be a true SLN that is too deep or covered by fat/other tissue for the NIR fluorescence to penetrate and be detected, a limitation dictated by the Beer–Lambert law governing light absorption in tissue.\n    b.  **Artifact**: It could be \"shine-through\" artifact from the nearby cervical injection site. Gamma rays from Tc-99m are highly penetrating, and if the injection depot is close to the pelvic sidewall, the collimated gamma probe can detect this signal, creating a false-positive \"hot spot\". The problem explicitly notes the presence of a \"cervical injection depot visible on the left,\" making this a high-priority possibility to investigate.\n\nA systematic approach must address all these possibilities based on the underlying physics and the clinical algorithm.\n\n1.  **Troubleshoot the Hot, Non-Fluorescent Focus**: The most pressing issue is to determine if the $1500$ cps focus is a true node or an artifact.\n    -   **Shine-Through**: The standard maneuver to rule out shine-through is to shield the injection site (e.g., with a lead-lined instrument, or even a dense, wet laparotomy sponge) and re-measure the counts at the focus. A dramatic drop in counts indicates shine-through. Another technique is triangulation: pointing the probe at the focus from different angles. If the signal is highest when the probe is aimed more towards the cervix, shine-through is likely. If the signal is highest when pointed directly at a specific anatomical point from all angles, a true hot node is likely.\n    -   **Lack of Fluorescence**: Concurrently, the lack of ICG signal should be investigated. This involves optimizing NIR imaging conditions: darkening the room completely, maximizing camera gain without introducing excessive noise, and ensuring optimal camera focus. Most importantly, gentle mobilization or dissection of overlying tissue (fat, peritoneum) can reduce the path length for light, potentially revealing a fluorescent signal from a deeper node.\n    -   **Anatomical Confirmation**: After localization with the probe, the surgeon must visually and tactilely (with instruments) confirm that the focus corresponds to a discrete lymph node structure, ideally with an afferent blue or green lymphatic channel leading to it (though this is not always visible).\n\n2.  **Apply the Discordance Algorithm**: Established guidelines for endometrial cancer SLN mapping are clear: any node that is hot-only, ICG-only, or hot+ICG is to be considered a sentinel node and removed.\n    -   Therefore, the ICG-positive/low-count node should be harvested.\n    -   The gamma-avid/non-fluorescent focus, *if confirmed to be a discrete node after ruling out shine-through*, must also be harvested.\n\n3.  **Ex Vivo Confirmation**: After removal, both specimens should be assessed on the back table, away from the patient. The gamma counts of the hot node are re-checked to confirm its intrinsic radioactivity, definitively separating it from in-situ shine-through. Both nodes are examined with the NIR camera to confirm or disconfirm fluorescence without tissue attenuation.\n\n4.  **Contingency Plan**: If, after this thorough troubleshooting, a definitive SLN cannot be identified on the left side (e.g., the hot spot is confirmed as shine-through and no other nodes are found), the mapping on that side is considered a failure. The standard of care in this situation is to proceed with a side-specific lymphadenectomy to ensure adequate surgical staging.\n\n### Option-by-Option Analysis\n\n**A. First shield the cervical injection site to reduce gamma shine-through and re-orient the gamma probe to interrogate the hot focus from multiple angles; concurrently optimize NIR imaging by further reducing ambient light, adjusting camera gain and focus, and gently mobilizing overlying fat to decrease path length; confirm that the hot focus corresponds to a discrete nodal structure with a lymphatic pedicle rather than contamination; then harvest both the ICG-positive low-count node and the gamma-avid non-fluorescent node with ex vivo confirmation of gamma counts and NIR signal; if mapping remains discordant or fails unilaterally after optimization, proceed with side-specific lymphadenectomy per guideline.**\n-   This option outlines a comprehensive, logical, and step-by-step troubleshooting protocol. It correctly identifies shine-through as a primary concern and describes the standard methods to test for it (shielding, triangulation). It addresses the limitations of NIR imaging (tissue attenuation) and describes appropriate optimization steps. It adheres to the established clinical algorithm of removing all tracer-positive nodes (both the ICG-positive and the gamma-avid one, if confirmed). It includes the critical steps of *ex vivo* confirmation and the correct contingency plan (side-specific lymphadenectomy). This procedure maximizes the chances of identifying the true SLN(s) while minimizing errors.\n-   **Verdict: Correct**\n\n**B. Ignore the ICG-positive node due to its low gamma counts and remove only the hottest gamma focus, attributing the lack of fluorescence to deep location, without further optimization or verification steps.**\n-   This approach is flawed. It violates the core principle of dual-tracer mapping, which dictates that a node positive for *either* tracer is a candidate SLN. Ignoring the ICG-positive node could lead to a false-negative result (missing a true SLN). Furthermore, it accepts the hot focus as a node without any verification, risking the removal of non-nodal tissue due to a shine-through artifact. This is an unsafe and incomplete strategy.\n-   **Verdict: Incorrect**\n\n**C. Abandon the current mapping by immediately re-injecting both technetium-99m and ICG and restarting the procedure, discarding any nodes currently identified to avoid discordance.**\n-   This is an illogical and counterproductive action. Re-injection would disrupt the lymphatic drainage pathways, making it impossible to identify the *first* draining node. It would contaminate the field and lead to tracer uptake in secondary and tertiary nodes. The existing discordant data is valuable and must be investigated, as discordance is a known and manageable phenomenon.\n-   **Verdict: Incorrect**\n\n**D. Attribute the hot, non-fluorescent focus to cervical injection-site shine-through and avoid removing any node on the left side; proceed only with contralateral mapping, since bilateral mapping is not required when one side is adequate.**\n-   This option makes an unverified assumption that the hot focus is shine-through. This must be tested, not assumed. It incorrectly suggests ignoring the ICG-positive node that has already been identified. Finally, the premise that \"bilateral mapping is not required when one side is adequate\" is contrary to current standards of care for endometrial cancer, which require bilateral pelvic node assessment for staging. Failure to map one side mandates a full lymphadenectomy on that side. This approach would result in inadequate staging.\n-   **Verdict: Incorrect**\n\n**E. Clip the lymphatic channel proximal to the fluorescent node to prevent further tracer spread, then increase NIR excitation power and rely exclusively on fluorescence to select the node, setting the gamma probe aside on the left.**\n-   This is procedurally incorrect. Clipping lymphatic channels is not a standard part of SLN mapping and could alter drainage patterns. Relying exclusively on one tracer when two were used defeats the purpose of the dual-tracer technique, which is to combine the strengths of both (penetrance of gamma rays and high-contrast visualization of ICG). The gamma-avid focus must be investigated, not ignored.\n-   **Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4508888"}]}